#USA #Tampa #TuHURA Biosciences #TBS-2025 #VISTA-inhibiting antibody

TuHURA Biosciences Takes a Major Step in Cancer Treatment

In a noteworthy advancement within the field of immuno-oncology, TuHURA Biosciences, Inc. (NASDAQ: HURA), has received the much-anticipated "Study May Proceed" notice from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application regarding TBS-2025, a VISTA-inhibiting antibody. This groundbreaking therapy is poised to be evaluated in specific molecularly defined subsets of Acute Myeloid Leukemia (AML) and other blood-related cancers.

A Landmark FDA Clearance

The FDA's approval allows TuHURA to initiate a Phase 1b clinical trial focusing on the safety and potential efficacy of TBS-2025 as a monotherapy for patients suffering from relapsed or refractory (r/r) mutNPM1 AML. This patient demographic has previously demonstrated a lack of effective treatment options, particularly after menin inhibitor therapy has failed. The upcoming Phase 1b study is designed to establish a safe and biologically effective dose of TBS-2025.

Addressing Unmet Medical Needs

Patients with r/r mutNPM1 AML represent a significant unmet medical need in the oncology sector. The development of TBS-2025 targets a patient population that has no currently approved therapies, raising hopes that this innovative treatment could lead to improved outcomes. If favorable results emerge from the dose-optimization phase of the study, TuHURA plans to discuss further trial expansions with the FDA, potentially aiming for accelerated approval.

Dr. James Bianco, President and CEO of TuHURA Biosciences, expressed enthusiasm over this milestone, emphasizing the company's commitment to enhancing treatment solutions for AML patients. He remarked, "As the only known company advancing a VISTA-inhibiting mAb through the FDA's IND process, this is a major milestone for the Company and a testament to our commitment to advancing novel therapies."

The Mechanism Behind TBS-2025

TBS-2025 emerges as a unique VISTA-inhibiting monoclonal antibody that plays a critical role in interrupting a key pathway through which AML cells evade recognition by the immune system. This evasion is largely attributed to the expression of VISTA, a checkpoint target found on quiescent T cells and myeloid cells, including Myeloid-Derived Suppressor Cells (MDSCs). Research indicates that the presence of VISTA on leukemic cells correlates with poor patient response to therapies and decreased survival rates.

Significantly, preliminary studies involving murine models of human AML indicated that TBS-2025 can block VISTA's effects, yielding dramatically improved survival outcomes—on par with current chemotherapy regimens. When TBS-2025 was used in conjunction with intensive chemotherapy, the survival rates exhibited even further improvements.

About TuHURA Biosciences

TuHURA Biosciences, Inc. is at the forefront of developing immuno-oncology therapeutics, specifically engineered to overcome primary and acquired resistance faced by cancer therapies. Their leading product candidate, IFx-2.0, is currently undergoing a randomized Phase 3 trial as an adjunct treatment alongside Keytruda® for advanced Merkel Cell Carcinoma.

In addition to TBS-2025, TuHURA is innovating other therapeutic approaches, including first-in-class bi-functional antibody drug conjugates aimed at suppressing tumor-promoting myeloid cells.

Conclusion

TuHURA's recent FDA clearance represents a promising leap forward in the fight against blood cancers, particularly AML. As they embark on this clinical trial, the potential implications for patient care and treatment efficacy are significant. For ongoing updates on TuHURA's journey and innovations, stakeholders are encouraged to visit the company's official website and follow their announcements through various social media platforms.

In a rapidly evolving landscape in cancer treatment, TBS-2025 could be a game-changer for many, providing renewed hope in an arena where historically there have been limited options for success.